Response's NT-proBNP CHF (congestive heart failure) test:
This article was originally published in Clinica
Executive Summary
Canadian regulators have given Response Biomedical approval to market its test for the congestive heart failure (CHF) marker NT-proBNP. The test, which is run of the firm's portable RAMP platform, is designed to help diagnose and assess severity in individuals suspected of having CHF, and may aid in the risk stratification of patients with acute coronary syndrome and heart failure. The British Columbia, Canada-based firm is one of several companies that markets a CHF test based on NT-proBNP or its biologically-active counterpart, BNP. RAMP NT-proBNP is already available in Europe and is pending US FDA clearance.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.